news
AI and cloud computing used to develop COVID-19 vaccine
A potential COVID-19 vaccine has been developed by researchers using AI and cloud computing to prevent the Spike protein from binding to the ACE2 receptor on human cells.
List view / Grid view
Immunology
video
Video: Increased reproducibility with KingFisher™ instruments
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.
news
Collaboration to develop inhaled mRNA-based antibody therapy for COVID-19
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
news
Macrophages identified as drug target for serous cavity cancers
The loss of RXR function, a molecular mechanism which determines the identity macrophages, has been revealed as a drug target for cancers in serous cavities.
news
Novel COVID-19 vaccine shows efficacy in mice
Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
article
How are seasonal influenza vaccines developing?
With the global ageing population at risk of death from influenza, what is pharma doing to develop more effective vaccines to combat the virus?
news
Biotech and academia collaborate on intranasal COVID-19 vaccine development
The University of Alabama at Birmingham (UAB) will run the pre-clinical trials of Altimmune’s intranasal COVID-19 vaccine candidate, AdCOVID.
news
Researchers develop CAR-T therapy that targets multiple leukaemia sites
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
news
Novel CAR T-cell immunotherapy eradicates solid tumours in mice
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
news
Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
news
Johnson & Johnson identifies lead COVID-19 vaccine candidate
A lead COVID-19 vaccine candidate has been selected by Johnson & Johnson, after demonstrating promise in pre-clinical testing.
news
Genetic deletion permanently prevented type 1 diabetes development in mice
Researchers observed that deleting the IRE1-alpha gene caused beta cells to de-differentiate and then re-differentiate in mice, preventing immune system auto-activation.
news
FDA and BARDA to collaborate with Grifols on COVID-19 therapeutics
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
news
Removing macrophages shows success against ovarian cancer in mice
By removing two kinds of macrophages in mice, researchers showed that ovarian tumours in mice were reduced in size and stopped spreading.
article
Antibodies allow for a targeted approach to cancer therapy
Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has an ever-expanding arsenal of therapies designed to thwart it, with variable levels of success. Nikki Withers speaks to Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer…